Skip to content
  • People
  • Pipeline
  • Publications
  • News
Menu
  • People
  • Pipeline
  • Publications
  • News
  • People
  • Pipeline
  • Publications
  • News
  • Contact us
Menu
  • People
  • Pipeline
  • Publications
  • News
  • Contact us
Contact

New Interview in Scrip

September 13, 2021

New interview in Scrip! Read more about our novel approach to CNS drug development and our focus on repurposing existing drugs with the aid of digital biomarkers.

Read the interview here.

For further information, contact:

Jenny Barnett, CEO

E: jbarnett@monumenttx.com

Media:

Richard Hayhurst/Janet Joy

E: Richard@rhapr.eu or jan@rhapr.eu

Tel: +44 7711 821527

Notes to Editors:

About Monument Therapeutics

Monument Therapeutics is bringing stratified medicine to neuroscience drug development. The company uses proprietary digital biomarkers to reduce heterogeneity and identify patients with homogenous underlying neurobiology, which are then matched with appropriately targeted compounds.

For further information visit www.monumenttx.com

Share on facebook
Share on twitter
Share on linkedin
PrevOlder
NewerNext

Contact Us

We believe that neuroscience will be in the next decade what oncology has been in the last decade.
Get in touch
MT LOGO WHITE PNG-01
info@monumenttx.com
© Copyright 2023  |  Privacy Policy & Terms of Use